ArticleAlzheimer's & dementia (New York, N. Y.)
Association between plasma p-tau181 levels and the evolution of cognitive and physical performance in a cohort of cognitively impaired older adults with frailty criteria: Longitudinal data from the CogFrail study.
Article in Alzheimer's & dementia (New York, N. Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEvidence linking plasma phosphorylated tau (p-tau)181 to cognitive decline comes from studies conducted in younger, selected research populations, raising questions about the generalizability of these findings to older adults meeting frailty criteria. The association between plasma p-tau181 and physical parameters has been sparsely investigated. This study aims to assess the relationship between plasma p-tau181 levels and the trajectories of cognitive and physical performance in a population of pre-frail and frail older adults.
methodsThis is a 2-year analysis based on longitudinal data from the CogFrail study. Plasma p-tau181 was measured using the SIMOA method. High p-tau181 levels were defined by a cut-off corresponding to the highest tertile of its distribution. Longitudinal changes from baseline in functional/cognitive (Mini-Mental State Examination [MMSE], Clinical Dementia Rating Sum of Boxes [CDR-SoB], Activities of Daily Living [ADL]-Index) and physical outcomes (gait speed, handgrip strength, Short Physical Performance Battery, and chair rise time) according to plasma p-tau181 status (high vs. low/intermediate levels) were compared using linear mixed-effects models.
resultsAmong the 227 patients with available plasma p-tau181 concentrations (mean age: 82.1 ± 5.1 years, 63.4% women), 77 (33.9%) were classified as having high plasma p-tau181 levels. Mean plasma p-tau181 values were 14.64 (± 3.83) and 29.96 (± 7.63) pg/mL in the low/intermediate and high level groups, respectively. Over 2 years, participants with high p-tau181 levels showed greater progression in CDR-SoB ( DISCUSSION: In a population of pre-frail and frail older adults with cognitive impairment, individuals with elevated plasma p-tau181 levels showed greater cognitive and physical deterioration over a 2-year period. Age-related loss of proteostasis, responsible for amyloidopathy and associated tauopathy, may play a role not only in cognitive but also in physical decline, representing a potential target for preventive and therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.